Cargando…
Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study
Autores principales: | Paul, Jim, Iveson, Tim, Midgely, Rachel, Harkin, Andrea, Masterton, Michelle, Alexander, Laura, Cassidy, Jim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287745/ http://dx.doi.org/10.1186/1745-6215-12-S1-A30 |
Ejemplares similares
-
Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
por: Boyd, Kathleen A, et al.
Publicado: (2011) -
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
por: Iveson, Timothy J, et al.
Publicado: (2018) -
Design choices for small-scale phase II trials with non-inferiority (NI) intention
por: Sun, Hong, et al.
Publicado: (2011) -
Variation of telomeric repeats in Scots pine (Pinus sylvestris) – is there a connection to ageing and loss of regeneration ability?
por: Aronen, Tuija
Publicado: (2011) -
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
por: Robles-Zurita, José, et al.
Publicado: (2018)